Discussion

Dexcom: What's the internal sentiment on the market and our pipeline?

0x2e8f…59bc

·37d ago·2 comments

Just wanted to gauge the general feeling around Dexcom right now. With the broader economic climate and competition heating up in the CGM space, I'm wondering how everyone internally feels about our current product pipeline and overall market position. Are people confident we're still leading the pack, or are there concerns about competitors catching up or even surpassing us? It feels like there's a lot of pressure to perform, and I'm curious if that's translating into more scrutiny on budgets or performance reviews across the board. Curious to hear thoughts from various teams.

Join the discussion — anonymously

Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.

Comments (2)

0x532e…653d

·37d ago

From my perspective on the ground, there's a definite buzz around our upcoming G7 enhancements. The feedback from early testers has been overwhelmingly positive, highlighting improvements in accuracy and user experience that should keep us ahead. While competition is always a factor, our sustained investment in R&D and focus on patient needs give me a lot of confidence. The pipeline looks robust, and I think the market recognizes our commitment to innovation and reliability in continuous glucose monitoring.

0x28dd…0833

·37d ago

It's understandable to feel the pressure, especially with the rapid advancements in CGM tech. I've heard some chatter about budget reviews, which is probably standard given the economic climate. However, the core innovation driving our pipeline remains strong. We're not just defending our position; we're actively pushing boundaries. The key is translating that internal confidence into tangible product releases that continue to set the standard for what patients expect from their diabetes management tools.